ABSTRACT
ObjectiveTo analyze the epidemic intensity and characteristics of influenza in Changzhou City， Jiangsu Province from 2019 to 2023， and to provide scientific evidence for the formulation of influenza prevention and control strategies. MethodsThe surveillance data of influenza surveillance sentinel hospitals in Changzhou City from April 2019 to March 2023 were collected through the China influenza surveillance information system. Influenza-like illness （ILI） cases before and after the pandemic of COVID-19 in Changzhou City were analyzed， and the differences among qualitative data were compared by using χ² test. ResultsFrom April 2019 to March 2023 the percentages of ILI cases’ medical visits in the four-influenza surveillance year were 2.57%， 1.84%， 5.38%， and 3.66%， respectively， and the positive detection rates of influenza virus were 25.71%， 0.44%， 22.78%， and 24.32%， respectively. The number of influenza outbreaks was 61， 1， 23， and 128， respectively. ILI cases were mainly among adolescent children aged 5‒14 years. The percentage of ILI cases in 2020‒2021 after the pandemic of COVID-19 was significantly lower than that in 2019‒2020 （χ2=737.342， P<0.001）， and the percentage of ILI cases in 2021‒2023 was higher than that in 2019‒2020. Influenza viruses in 2019‒2021 were dominated by type B Victoria， and influenza A virus was the dominant strain in positive influenza virus detections in 2022‒2023. The number of influenza outbreaks in 2021‒2023 was significantly lower than that in 2019‒2020 （χ2=185.662， P<0.001）. ConclusionThe epidemiological characteristics of influenza are different in different stages of COVID-19 prevention and control during 2019‒2023. In the dynamic clearance phase of COVID-19， ILI case’s medical visits showed low-level fluctuations without obvious seasonal fluctuations， and influenza virus was dominated by type B. In the high-intensity phase of the pandemic， the level of ILI case’s medical visits has reached the peak of the calendar year， and the positive detection of influenza virus was dominated by type A H3N2. In the "Category B B control" phase， the level of ILI case’s medical visits increased after a rapid decline， and the positive detection of influenza virus was dominated by type A H1N1. It is necessary to further strengthen the monitoring of influenza cases， pay close attention to the changes in influenza strains， actively promote influenza vaccination for key population group， and promote health behavior changes for the whole population.
ABSTRACT
OBJECTIVE:To evaluate the clinical efficacy of somatostatin and protease inhibitors in the prevention of post-ERCP pancreatitis(PEP)and hyperamylasemia(PEHA). METHODS:Retrieved from databases as Cochrane Library, PubMed,Embase,RCTs about therapeutic efficacy of somatostatin and protease inhibitors in the prevention of PEP were included. EndNote X8 software was used to eliminate duplicate documents,and the quality of included studies was evaluated according to Cochrane System Evaluator Manual version 5.3.3. Bayesian network Meta-analysis was conducted by MCMC method with R 3.4.3 software Gemtc 0.8 program package. Risk of bias was evaluated by using Rev Man 5.3 software,and risk of publication was evaluated by using Stata 14.0 software draws funnel map. RESULTS:A total of 33 RCTs were included,involving 10 576 patients,somatostatin,gabexate,ulinastatin,nafamostat. Network Meta-analysis showed that in the prevention of PEP,the order of curative effect was as follows:somatostatin(intravenous bolus)>nafamostat>ulinastatin>somatostatin(high-dose intravenous drip)>gabexate,somatostatin(low-dose intravenous drip)was ineffective. In the prevention of PEHA,the order of probability being somatostatin(high-dose intravenous drip)>somatostatin(intravenous bolus)>ulinastatin. Only nafamostat was effective in preventing PEP in high-risk patients. CONCLUSIONS:Compared with somatostatin(low-dose intravenous drip)and gabexate,somatostatin(intravenous bolus)and somatostatin(high-dose intravenous drip),ulinastatin,nafamostat can more effectively prevent PEP. Nafamostat cannot prevent PEHA,but can prevent PEP in high risk patients.
ABSTRACT
OBJECTIVE:To provide reference for improving the drug procurement system of public hospitals in China. METH-ODS:The drug collective procurement documents in each province were retrieved after publishing the document [2015] No.7 of the State Council and the document [2015] No.70 of the National Health and Family Planning Commission,the drug bidding data was collected,and form and implementation of drug procurement with target quantity were analyzed. RESULTS:Procurement with tar-get quantity included scattered procurement with target quantity,national centralized procurement with target quantity and provin-cial centralized procurement with target quantity. In scattered procurement with target quantity,actual purchase price was opaque, and the procurement was similar to"second negotiation"in individual province. National centralized procurement with target quanti-ty was implemented well. Provincial centralized procurement with target quantity was not fully implemented,only Shanghai carried out centralized procurement with target quantity,and the pilot had good effects. CONCLUSIONS:In order to promote procurement with target quantity,it's suggested that we should definite"procurement with target quantity"in the governmental document,pub-lish actual procurement price of scattered procurement with target quantity,try to implement centralized procurement with target quantity without quality levels distinguished,improve the centralized procurement with target quantity with quality levels distin-guished and improve supporting measures,such as hospital procurement system,provincial procurement platform, pre-payment mechanism by health-care funds,and so on.